GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus is the diagnostics market for cancer. The concept of personalized medicine becomes increasingly important in oncology. The identification of the right drug for the individual patient is todays challenge in clinical practice. To address this medical need, the GILUPI CellCollector®
is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers in various cancer types. Isolated cells can be characterized and analyzed down to a molecular level with immunostaining, DNA- or RNA-based methods. The GILUPI CellCollector®
is the first in vivo CTC isolation product that is CE approved.